HDL increasing drugs

Torcetrapib      

Select            
Trial Studied trt Control trt patientstagsROB Trial resultAll cause deathCoronary event

cardiovascular prevention

anacetrapib
DEFINE, 2010    NCTanacetrapibplaceboExploratory negative38%
REALIZE, 2015      NCTanacetrapibplaceboLow risk of bias negative
bezafibrate
BECAIT, 1996     bezafibrateplacebosecondary preventionExploratory suggesting+Infini%-75%
BIP, 2000       bezafibrateplacebosecondary preventionLow risk of bias negative6%-9%
SENDCAP, 1998     bezafibrateplacebo type 2 diabetes Exploratory suggesting-100%-64%
LEADER, 2002     bezafibrateplaceboLow risk of bias negative5%-19%
clofibrate
WHO clofibrate, 1978   clofibrateplaceboLow risk of bias suggesting 27%-17%
CDP Clofibrate, 1975   clofibrateplaceboLow risk of bias suggesting -2%-7%
Scottish, 1971   clofibrateplaceboLow risk of bias negative-2%-19%
Newcastle, 1971   clofibrateplaceboLow risk of bias suggesting-37%-37%
Harrold, 1969   clofibrateplacebo type 2 diabetes Low risk of bias -
Begg, 1971   clofibrateplacebosecondary preventionExploratory negative-58%
Acheson, 1972   clofibrateplacebosecondary prevention cerebral vascular disease Exploratory -
VA Neurology Section, 1974   clofibrateplaceboLow risk of bias -
Cullen, 1974   clofibrateplaceboLow risk of bias -
Hanefeld, 1991   clofibrateplacebo type 2 diabetes Low risk of bias negative4%
etofibrate
Emmerich, 2009     etofibrateplacebodiabetic type 2 diabetes Exploratory -
fenofibrate
FIELD, 2005             fenofibrateplacebodiabetic type 2 diabetes Low risk of bias suggesting 10%-11%
DAIS, 2001     fenofibrateplacebodiabetic type 2 diabetes Exploratory negative-32%-23%
ACCORD lipid, 2010    NCTfenofibrateplacebo (on top simvastatine)diabetic patientsLow risk of bias negative-9%-6%
gemfibrozil
VA-HIT, 1999      NCTgemfibrozilplaceboLow risk of bias suggesting-10%-20%
Helsinki (HHS), 1987   gemfibrozilplaceboLow risk of bias suggesting2%-34%
HHS (Frick)(secondary prev subgroup), 1993   gemfibrozilplaceboExploratory negative61%
LOCAT, 1997     gemfibrozilplaceboExploratory negative1%
niacin
VA drugs, 1968   niacincontrolLow risk of bias negative3%
CDP niacin, 1975   niacinplaceboLow risk of bias suggesting-4%-15%
AIM-HIGH, 2011      NCTniacinplacebo (on top statin)Low risk of bias negative4%
HPS 2-Thrive      NCTniacinplacebo (on top statin)Low risk of bias negative9%-4%
Oxford Niaspan Study, 2009    NCTniacinplacebo (on top statin)Exploratory -
ARBITER 2, 2009   niacinplacebo (on top statin)Exploratory negative-8%
HATS, 2001   niacinplacebo (on top statin)Low risk of bias negative-80%
ARBITER 6-HALTS (niacin vs ezetimibe), 2009        NCTniacinezetimibeExploratory suggesting -79%
torcetrapib
RADIANCE 1, 2007      NCTtorcetrapibplaceboExploratory negative-100%
ILLUMINATE, 2007      NCTtorcetrapibplaceboLow risk of bias negative 58%22%
RADIANCE 2, 2007     torcetrapibplaceboLow risk of bias -
ILLUSTRATE, 2007      NCTtorcetrapibplaceboExploratory negative35%